Analysts See $-0.06 EPS for DURECT Corporation (DRRX)

July 14, 2018 - By Sheila Pollock

DURECT Corporation (NASDAQ:DRRX) LogoInvestors sentiment decreased to 1.71 in Q1 2018. Its down 0.33, from 2.04 in 2017Q4. It fall, as 6 investors sold DURECT Corporation shares while 22 reduced holdings. 20 funds opened positions while 28 raised stakes. 70.89 million shares or 9.45% more from 64.77 million shares in 2017Q4 were reported.
Deutsche Bankshares Ag holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 188,714 shares. Price T Rowe Md owns 0% invested in DURECT Corporation (NASDAQ:DRRX) for 94,242 shares. Stratos Wealth Partners Ltd has invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Moreover, Plante Moran Lc has 0% invested in DURECT Corporation (NASDAQ:DRRX) for 676 shares. Millennium Management Ltd Liability Corporation accumulated 0% or 686,685 shares. Balyasny Asset Mgmt Ltd Liability Corporation has 29,666 shares for 0% of their portfolio. Thompson Davis & invested in 0.06% or 10,838 shares. Engineers Gate Manager L P invested in 101,945 shares. 25,380 are owned by Principal Group. Barclays Public Limited Company holds 0% or 35,847 shares. Rhumbline Advisers invested in 130,625 shares or 0% of the stock. Manufacturers Life Ins The stated it has 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). Stoneridge Invest Prns Ltd Liability Corp reported 14,463 shares. Proshare Advisors Limited Liability Corporation, a Maryland-based fund reported 18,339 shares. Geode Cap Mngmt Ltd Liability Com holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 1.38 million shares.

Analysts expect DURECT Corporation (NASDAQ:DRRX) to report $-0.06 EPS on August, 14.They anticipate $0.01 EPS change or 14.29 % from last quarter’s $-0.07 EPS. After having $-0.05 EPS previously, DURECT Corporation’s analysts see 20.00 % EPS growth. The stock increased 1.83% or $0.03 during the last trading session, reaching $1.67. About 283,458 shares traded. DURECT Corporation (NASDAQ:DRRX) has risen 56.35% since July 14, 2017 and is uptrending. It has outperformed by 43.78% the S&P500.

DURECT Corporation (NASDAQ:DRRX) Ratings Coverage

Among 2 analysts covering Durect Corp (NASDAQ:DRRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Durect Corp had 2 analyst reports since March 2, 2018 according to SRatingsIntel. The company was maintained on Friday, March 2 by Stifel Nicolaus. The stock of DURECT Corporation (NASDAQ:DRRX) has “Buy” rating given on Tuesday, March 6 by H.C. Wainwright.

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company has market cap of $270.05 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. It currently has negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.

More news for DURECT Corporation (NASDAQ:DRRX) were recently published by: Streetinsider.com, which released: “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” on June 27, 2018. Streetinsider.com‘s article titled: “After-Hours Stock Movers 06/26: (DAC) (WWE) Higher; (DRRX) (SONC) (SBLK) Lower (more…)” and published on June 26, 2018 is yet another important article.

DURECT Corporation (NASDAQ:DRRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: